Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Aug 8;30(4):474.
doi: 10.3892/ol.2025.15220. eCollection 2025 Oct.

Dialysis independence for a young patient with refractory multiple myeloma treated with teclistamab: A case report

Ioannis Ntanasis-Stathopoulos  1 , Ilias Katsadouros  1 , Panagiotis Malandrakis  1 , Erasmia Psimenou  1 , Meletios-Athanasios Dimopoulos  1   2 , Maria Gavriatopoulou  1
Affiliations
Case Reports

Dialysis independence for a young patient with refractory multiple myeloma treated with teclistamab: A case report

Ioannis Ntanasis-Stathopoulos et al. Oncol Lett. .

Abstract

Teclistamab, a B-cell maturation antigen-targeting bispecific antibody, offers a promising treatment option for relapsed/refractory multiple myeloma (RRMM), even in patients with severe renal impairment. The present study describes the case of a 47-year-old woman with RRMM who achieved minimal residual disease negativity and dialysis independence following teclistamab treatment. Despite prior resistance to multiple therapies, including an anti-CD38 monoclonal antibody (daratumumab), two proteasome inhibitors (bortezomib and carfilzomib), an immunomodulatory drug (lenalidomide), an exportin 1 inhibitor (selinexor), a BCL-2 inhibitor (venetoclax) and dexamethasone, and post-autologous stem cell transplantation relapse, teclistamab induced a deep hematological response. Cytokine release syndrome was manageable and no major complications occurred. The present case highlights the feasibility and effectiveness of teclistamab in patients with end-stage renal disease.

Keywords: B-cell maturation antigen; bispecific antibody; dialysis; multiple myeloma; relapsed/refractory; renal impairment; teclistamab.

PubMed Disclaimer

Conflict of interest statement

INS declares honoraria from Janssen. PM declares honoraria from Janssen. MAD declares honoraria from Abbvie, Amgen, Bristol Myers Squibb, GSK, Janssen, Karyopharm, Pharmacyclics Inc, Pfizer, Sanofi, and Takeda. MG declares honoraria from GSK, Janssen, Sanofi, Abbvie, Amgen, and Takeda. The other authors declare that they have no competing interests.

Figures

Figure 1. A schematic overview of the succession of treatments and fluctuation of serum dFLC levels during the disease course. FLC, free light chains; MR, minor response; PR, partial response; VGPR, v...
Figure 1.
A schematic overview of the succession of treatments and fluctuation of serum dFLC levels during the disease course. FLC, free light chains; MR, minor response; PR, partial response; VGPR, very good partial response; sCR, stringent complete remission; MRD, minimal residual disease; PD, progressive disease; Ven, venetoclax; Dara, daratumumab; V, bortezomib; R, lenalidomide; d, dexamethasone; C, cyclophosphamide; HDM, high dose melphalan; ASCT, autologous stem cell transplant; Sel, selinexor; K, carfilzomib.
See this image and copyright information in PMC

References

    1. Kleber M, Ntanasis-Stathopoulos I, Terpos E. BCMA in multiple Myeloma-A promising key to therapy. J Clin Med. 2021;10:4088. doi: 10.3390/jcm10184088. - DOI - PMC - PubMed
    1. Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495–505. doi: 10.1056/NEJMoa2203478. - DOI - PMC - PubMed
    1. Dimopoulos MA, Merlini G, Bridoux F, Leung N, Mikhael J, Harrison SJ, Kastritis E, Garderet L, Gozzetti A, van de Donk NWCJ, et al. Management of multiple myeloma-related renal impairment: Recommendations from the International Myeloma Working Group. Lancet Oncol. 2023;24:e293–e311. doi: 10.1016/S1470-2045(23)00223-1. - DOI - PubMed
    1. Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6:576–588. doi: 10.1002/psp4.12224. - DOI - PMC - PubMed
    1. Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, Balev M, Patwari A, Cheruvalath H, Bhutani D, et al. Teclistamab in relapsed refractory multiple myeloma: Multi-institutional real-world study. Blood Cancer J. 2024;14:35. doi: 10.1038/s41408-024-01003-z. - DOI - PMC - PubMed

Publication types

LinkOut - more resources